The aim of modelling is to guide the prioritization of clinical drugs development. The presentation seems to FOCUS on drugs already being developed for COVID. Which drugs are high priority, which ones are not??
This is a real-time effort, and simulations in silico are hand-in-glove with clinical trials. They play off of each other. Here, we show tools to help inform clinical trial design (which they are), and then we’ll move to take that clinical data to update our models. Learn-Confirm.
You must be logged in to reply to this topic.
For comments and inquiries about the COVID-19 Pharmacology Resource Center, please fill out the Contact Us form, and we will be in touch shortly.